

# Theravance Biopharma

## Third Quarter 2025 Financial Results and Business Update

November 10, 2025

THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third-party trademarks used herein are the property of their respective owners.

© 2025 Theravance Biopharma. All rights reserved.

# Forward Looking Statements

This presentation contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma, Inc. (the "Company") intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.

Examples of such statements include statements relating to: the Company's expectations regarding its future profitability, expenses and uses of cash, the Company's goals, designs, strategies, plans and objectives, future growth of YUPELRI sales, the ability to provide value to shareholders, the Company's regulatory strategies and timing of clinical studies, possible safety, efficacy or differentiation of our investigational therapy, commercial potential and market opportunity of our investigational therapy, the status of patent infringement litigation initiated by the Company and its partner against certain generic companies in federal district courts; contingent Trelegy sales-based milestones payable by Royalty Pharma, and expectations around the use of OHSAs as endpoints for clinical trials. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of this presentation and the conference call and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: factors that could increase the Company's cash requirements or expenses beyond its expectations and any factors that could adversely affect its profitability, whether the milestone thresholds can be achieved, delays or difficulties in commencing, enrolling or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's product candidates or product are unsafe, ineffective or not differentiated, risks of decisions from regulatory authorities that are unfavorable to the Company, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop, manufacture and commercialize products, and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure, the ability of the Company to protect and to enforce its intellectual property rights, volatility and fluctuations in the trading price and volume of the Company's shares, and general economic and market conditions.

Other risks affecting the Company are in the Company's Form 10-Q filed with the SEC on August 13, 2025, and other periodic reports filed with the SEC. In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

## Non-GAAP Financial Measures

Theravance Biopharma provides a non-GAAP profitability target and a non-GAAP metric in this presentation. Theravance Biopharma believes that the non-GAAP profitability target and non-GAAP net income (loss) provide meaningful information to assist investors in assessing prospects for future performance and actual performance as they provide better metrics for analyzing the performance of its business by excluding items that may not be indicative of core operating results and the Company's cash position. Because non-GAAP financial targets and metrics, such as non-GAAP profitability and non-GAAP net income (loss) are not standardized, it may not be possible to compare these measures with other companies' non-GAAP targets or measures having the same or a similar name. Thus, Theravance Biopharma's non-GAAP measures should be considered in addition to, not as a substitute for, or in isolation from, the Company's actual GAAP results and other targets.

This presentation contains a reconciliation of non-GAAP net income (loss) to its corresponding measure, net income (loss). A reconciliation of non-GAAP net income (loss) to its corresponding GAAP measure is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential variability of, expenses and other factors in the future.

# Agenda

**Opening & Closing Remarks**

**Rick Winningham:** Chief Executive Officer

**Commercial Updates**

**Rhonda Farnum:** Senior Vice President, Chief Business Officer

**Development & Regulatory Updates**

**Dr. Áine Miller:** Senior Vice President, Development

**TRELEGY & Financial Updates**

**Aziz Sawaf:** Senior Vice President, Chief Financial Officer

**Q&A**

**Team**

# Delivered Strong Q3 Results While Approaching a Major Catalyst



- Net sales of **\$71.4M**, an **all-time high**, representing 15% YoY growth<sup>1</sup>
- **On-track** to trigger **\$25M milestone** for achievement of \$250M of Net Sales<sup>2</sup>
- Total customer **demand increased 6% YoY<sup>3</sup>**; **hospital growth of 29% YoY<sup>4</sup>**

## Amprexetine

- Open-label portion of the pivotal Phase 3 CYPRESS study **now complete**
- Topline results **remain on track** for Q1 2026
- Clinical development program **featured in new publication & four presentations at 2025 AAS meeting**
- KOL event for investors featuring Dr. Horacio Kaufmann scheduled for **December 8, 2025**

TRELEGY ELLIPTA  
(fluticasone furoate, umeclidinium,  
and vilanterol inhalation powder)

Q3 Net Sales of ~\$1.0B / YTD Net Sales of ~\$2.9B, **on pace to trigger 2025 milestone of \$50M<sup>5</sup>**

## Financials

- **\$333M of cash** and no debt
- **\$75M of high-probability milestones** in the **near-term** (\$50M for TRELEGY | \$25M for YUPELRI)

## Rapidly Approaching Amprexetine Phase 3 Data Catalyst in Q1 2026

AAS, American Autonomic Society.

1. In the US, Viatris is leading the commercialization of YUPELRI, and Theravance Biopharma co-promotes the product under a profit and loss sharing arrangement (65% to Viatris; 35% to Theravance Biopharma).  
2. As of 09/30/25, Theravance Biopharma is eligible to receive from Viatris potential global development, regulatory and sales milestone payments (excluding China and adjacent territories) totaling up to \$205.0 million in the aggregate; refer to our SEC filings for further information. 3. Source: Viatris Customer Demand (Q3'25). 4. Source: IQVIA DDD, HDS, VA and Non-Reporting Hospital through Sep'25. 5. Source: GSK-reported Net Sales in USD. Pursuant to the Equity Purchase and Funding Agreement, dated as of July 13, 2022, by and between Theravance Biopharma, Inc. and Royalty Pharma Investments 2019 ICAV, Theravance is eligible to receive up to an additional \$150M in near-term TRELEGY sales milestones.





# The Only Once-Daily, Nebulized LAMA Maintenance Medicine for COPD

Co-promotion agreement with VIATRIS™ (35% / 65% Profit Share)

**Rhonda Farnum**  
**Senior Vice President, Chief Business Officer**

# Continued Year-over-Year YUPELRI® Net Sales Growth in the U.S.



**Net sales increased 15% Q3 '25 / Q3 '24**

# Strong Q3 Performance and Expanding YUPELRI® Profitability

## Growth in Q3 2025

- Q3 2025 U.S. net sales of \$71.4M up 15% vs. Q3 2024
- Hospital doses growth of 29% vs Q3 2024; new hospital market share high of 21%
  - Hospital setting serves as key point of initiation; majority of patients receive script at discharge<sup>1</sup>

## Continued Opportunity

- Sizable addressable patient population remains<sup>2</sup>
- Increasing adoption of concomitant use with LAMA/LABA and switches from handheld-only regimens
- Success in further diversification of product fulfillment
- New analyses presented at CHEST 2025 further strengthen evidence supporting YUPELRI use
- Eligible to receive tiered royalties ranging from 14% to 20% on net sales in China

## Profitable Brand, Expanding Margins and Strong IP

- Theravance receives 35% of U.S. profits<sup>3</sup>
- \$25M milestone for 1st year in which U.S. net sales > \$250M<sup>4</sup>
  - ~\$54 million required in Q4 2025 to trigger \$25 million milestone in 2025
- IP protection in the U.S. into 2039

LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist.

1. Joint VTRS/TBPH Market Research. 2. Addressable patient population quantifies the number of patients within the intended target profile. Source: Joint VTRS/TBPH Market Research. 3. In the US, Viatriis is leading the commercialization of YUPELRI, and Theravance Biopharma co-promotes the product under a profit and loss sharing arrangement (65% to Viatriis; 35% to Theravance Biopharma). 4. As of 9/30/25, Theravance Biopharma is eligible to receive from Viatriis potential global development, regulatory and sales milestone payments (excluding China and adjacent territories) totaling up to \$205.0 million in the aggregate; refer to our SEC filings for further information.

AMPRELOXETINE

**The first once-daily, selective norepinephrine reuptake inhibitor in development to treat symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)**

**Dr. Áine Miller**  
**Senior Vice President, Development**



# Recent Publications and Presentations Highlight Durable Symptom Benefit Observed in Previous REDWOOD/0170 Study in MSA Patients<sup>1</sup>

## Publications

**“Precision therapy with amprelosetine for neurogenic orthostatic hypotension in multiple system atrophy”** manuscript submitted, under review and pre-print posted on medRxiv

- Highlights **durable symptom and daily function improvement** in MSA subgroup from the REDWOOD study<sup>1</sup>

**“Establishing Minimally Clinically Important Differences for the Orthostatic Hypotension Questionnaire (OHQ)”** Kaufmann H, et al. manuscript published in *Clinical Autonomic Research*

- Defines meaningful change thresholds, enhancing clinical interpretation

## AAS Presentations




**36<sup>TH</sup> INTERNATIONAL SYMPOSIUM  
ON THE AUTONOMIC NERVOUS SYSTEM**

**One platform presentation and three poster presentations highlighting:**

- Results from the REDWOOD study in MSA subgroup
- Rigorous methodologies to support enrollment and patient retention in the ongoing Phase 3 CYPRESS study

# Amprelosetine Increase in Standing Blood Pressure Correlated with Improvement in Symptoms and Daily Activities in Patients with MSA in the REDWOOD/0170 Study<sup>1</sup>



**No signal for worsening of supine hypertension<sup>1</sup>**

MSA, multiple system atrophy; OHDAS, orthostatic hypotension daily activity scale; OHSA, orthostatic hypotension symptom assessment; RW, randomized withdrawal. Freeman R, et al. Precision therapy with amprelosetine for neurogenic orthostatic hypotension in multiple system atrophy. MedRxiv. <https://doi.org/10.1101/2025.08.12.25332833>. \*Longitudinal analysis of blood pressure at 3 minutes of standing at entry (Pre-treatment baseline), throughout the 16-week open-label period, and in the randomized withdrawal in the analysis population set of REDWOOD. \*\*Longitudinal analysis of mean OHQ symptom assessment composite scores, after censorship for early withdrawal, in the subgroup of randomized MSA patients. <sup>†</sup>Shows OHDAS item 1 scores capturing severity of interference of symptoms of nOH on standing for a short time. 1. Amprelosetine is in development and not approved for any indication. No conclusion can be drawn regarding its safety or efficacy.

# Ampreloxetine Clinical Development Status Update

## Phase 3 CYPRESS Trial

- Completed enrollment in August 2025
- Trial progressing as planned, with all patients completing the open-label portion of the trial
- **Topline results anticipated in Q1 2026**

## Regulatory and Commercial/Medical Activities

- Continued preparations for an expedited NDA submission
- If data are supportive, will request priority FDA review
- Pre-launch activities across medical affairs and commercial functions are underway

## Upcoming Virtual KOL Event for Investors with Dr. Horacio Kaufmann



**December 8, 2025 at 10:30 AM ET**

### Agenda

- High unmet need in nOH in patients with MSA
- Ampreloxetine clinical development
- Commercial opportunity

GSK's TRELEGY

# The First And Only Once-Daily Triple Therapy In a Single Inhaler For Adult Patients With COPD Or Asthma

Milestones from Royalty Pharma

**Aziz Sawaf**  
Senior Vice President, Chief Financial Officer




# On Pace to Achieve \$150M in TRELEGY Sales Milestones in 2025 and 2026

Q3'25 Net Sales of \$1.0B and YTD Net Sales of \$2.9B, up 13% YoY

## 2025 and 2026 Sales Milestones<sup>1</sup>

Year	Global Net Sales Equivalent	Royalty Threshold <sup>2</sup>	Milestone to Theravance
2025 <sup>1</sup>	\$3,063M	\$260M	\$25M
	\$3,413M	\$295M	\$50M
2026 <sup>1</sup>	\$3,163M	\$270M	\$50M
	\$3,513M	\$305M	\$100M

## Strong TRELEGY Global Net Sales Growth (\$M)



1. If both milestones are achieved in a given year, Theravance Biopharma will only earn the higher milestone, payable by Royalty Pharma (RP) pursuant to the Equity Purchase and Funding Agreement, dated as of July 13, 2022, by and between Theravance Biopharma, Inc. and Royalty Pharma Investments 2019 ICAV. 2. Based on 100% of TRELEGY ELLIPTA royalties. 3. GSK-reported Net Sales in USD. 4. Bloomberg Consensus as of 11/6/25.

# Financial Update

**Aziz Sawaf**

**Senior Vice President, Chief Financial Officer**



# Third Quarter 2025 Financials (Unaudited)

(\$, in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
	(Unaudited)		(Unaudited)	
<b>Revenue:</b>				
Viатris collaboration agreement	\$ 19,990	\$ 16,868	\$ 54,073	\$ 45,627
Licensing revenue	-	-	7,500	-
Total revenue	19,990	16,868	61,573	45,627
<b>Costs and expenses:</b>				
Research and development (1)	8,112	9,268	30,054	28,190
Selling, general and administrative (1)	18,333	16,875	55,132	50,673
Impairment of long-lived assets (non-cash)	-	1,562	-	4,513
Total costs and expenses	26,445	27,705	85,186	83,376
<b>Loss from operations (before tax and other income &amp; expense)</b>	<b>\$ (6,455)</b>	<b>\$ (10,837)</b>	<b>\$ (23,613)</b>	<b>\$ (37,749)</b>
<b>Share-based compensation expense:</b>				
Research and development	1,080	1,111	3,137	3,727
Selling, general and administrative	3,496	3,852	10,859	11,840
Total share-based compensation expense	4,576	4,963	13,996	15,567
<b>Operating expense excl. share-based compensation:</b>				
R&D operating expense (excl. share-based compensation)	7,032	8,157	26,917	24,463
SG&A operating expense (excl. share-based compensation)	14,837	13,023	44,273	38,833
<b>Total operating expenses excl. share-based compensation</b>	<b>\$ 21,869</b>	<b>\$ 21,180</b>	<b>\$ 71,190</b>	<b>\$ 63,296</b>
<b>Non-GAAP net income (loss) (2)</b>	<b>\$ 2,260</b>	<b>\$ (2,897)</b>	<b>\$ (10,583)</b>	<b>\$ (13,692)</b>

1. Amounts include share-based compensation. 2. Non-GAAP net income (loss) consists of GAAP net income (loss) before taxes excluding (i) share-based compensation expense; (ii) non-cash interest expense; (iii) non-cash impairment expense; and (iv) non-recurring revenue and income items; see reconciliation on Slide 16 and the section titled "Non-GAAP Financial Measures" on Slide 2 for more information.

# Third Quarter 2025 Financials (Unaudited)

## (Cont'd)

### Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income (Loss) (In thousands, except per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
	(Unaudited)		(Unaudited)	
<b>GAAP Net Income (Loss)</b>	\$ 3,615	\$ (12,698)	\$ 44,871	\$ (40,891)
<u>Adjustments:</u>				
Licensing revenue (1)	-	-	(7,500)	-
Net gain on realized contingent milestone and royalty assets (1)	-	-	(75,137)	-
Non-cash impairment expense of long-lived assets (1)	-	1,562	-	4,513
Share-based compensation expense	4,576	4,963	13,996	15,567
Non-cash interest expense	573	630	1,879	1,903
Income tax (benefit) expense	(6,504)	2,646	11,308	5,216
<b>Non-GAAP Net Income (Loss)</b>	<b>\$ 2,260</b>	<b>\$ (2,897)</b>	<b>\$ (10,583)</b>	<b>\$ (13,692)</b>
<b>Non-GAAP Net Income (Loss) per Share</b>				
Non-GAAP net income (loss) per share - basic	\$ 0.04	\$ (0.06)	\$ (0.21)	\$ (0.28)
Non-GAAP net income (loss) per share - diluted	\$ 0.04	\$ (0.06)	\$ (0.21)	\$ (0.28)
Shares used to compute non-GAAP net income (loss) per share - basic	50,520	49,038	50,137	48,690
Shares used to compute non-GAAP net income (loss) per share - diluted	51,908	49,038	50,976	48,690

(1) Non-recurring item

# Third Quarter 2025 Financial Highlights

Metric	Q3 '25 (M)	Q3 '24 (M)	Note
VIATRIS Collaboration Revenue	\$20.0	\$16.9	19% growth YoY driving improved profit margins
SG&A and R&D Expense, ex-SBC	\$21.9	\$21.2	
Share-Based Compensation	\$4.6	\$5.0	Down 8% YoY due to continued cost discipline
GAAP Net Income (Loss)	\$3.6	(\$12.7)	
Non-GAAP Net Income (Loss) <sup>1</sup>	\$2.3	(\$2.9)	
Cash and Cash Equivalents <sup>2</sup> (as of quarter-end)	\$332.7	\$91.4	Increase driven by TRELEGY royalty interest sale in second quarter of 2025
Debt (as of quarter-end)	\$0.0	\$0.0	
Shares Outstanding (as of quarter-end)	50.7	49.2	

SBC, Share-Based Compensation.

1. Non-GAAP net income (loss) consists of GAAP net income (loss) before taxes less (i) share-based compensation expense; (ii) non-cash interest expense; (iii) non-cash impairment expense; and (iv) non-recurring revenue and income items; see reconciliation on Slide 16 and the section titled "Non-GAAP Financial Measures" on Slide 2 for more information. 2. Cash, cash equivalents and marketable securities.

# Reaffirmed Operating Expense Guidance with Improved Margin Outlook

## 2025 OPEX Guidance:

- R&D (excluding share-based comp): \$32M - \$38M
- SG&A (excluding share-based comp): \$50M - \$60M
- Share-Based Compensation: \$18M - \$20M


## 2025 Non-GAAP Profit/(Loss) Guidance<sup>1</sup>:

- Achieved non-GAAP breakeven in Q3 2025
- Expect to remain at similar levels in Q4 2025
- Guidance excludes potential milestones for TRELEGY & YUPELRI

## Milestone Accounting:

- TRELEGY: If \$50M milestone achieved in Q4, \$50M recognized as Other Income in Q4'25
- YUPELRI: If \$25M milestone achieved in Q4, \$25M recognized as License Revenue in Q4'25

## Operating Expenses (\$M)



# Strong Financial Position and Cash-Generating YUPELRI® Set the Foundation for Ampreloxetine Phase 3 Catalyst in Q1 2026



## Ampreloxetine Upcoming Phase 3 Data

Completed **Phase 3 CYPRESS** enrollment in Q3 2025; topline data anticipated in Q1 2026

FDA Orphan Drug Designation

Targets **~40,000 underserved patients** in the U.S. with symptomatic nOH due to MSA<sup>1,2</sup>



## YUPELRI® Strong Cash Flow Generation

Launched in the U.S. in 2019; 35% U.S. profit share with Viatrix<sup>3</sup>

**Strong cash flow** from U.S. profit share with **IP protection** in the U.S. into **2039**

Sizable addressable patient population remains<sup>4</sup>



## Strong Financial Position

**~\$333M in cash and no debt**; breakeven in Q3 2025<sup>5</sup>, expected to remain at similar levels in Q4 2025

**\$175M** in near-term, high probability TRELEGY<sup>6</sup> and YUPELRI sales-based milestones

Commitment to **return excess capital** to shareholders

# Q&A Session

**Rick Winningham**  
Chief Executive Officer



**Aziz Sawaf, CFA**  
Senior Vice President,  
Chief Financial Officer



**Rhonda Farnum**  
Senior Vice President,  
Chief Business Officer



**Áine Miller**  
Senior Vice President,  
Development



# YUPELRI<sup>®</sup> (revefenacin) Inhalation Solution

YUPELRI<sup>®</sup> inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

## Important Safety Information (US)

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

# About YUPELRI<sup>®</sup> (revefenacin) Inhalation Solution

YUPELRI<sup>®</sup> (revefenacin) inhalation solution is a once-daily nebulized LAMA approved for the maintenance treatment of COPD in the US.

Market research by Theravance Biopharma indicates approximately 9% of the treated COPD patients in the US use nebulizers for ongoing maintenance therapy.<sup>1</sup> LAMAs are a cornerstone of maintenance therapy for COPD and YUPELRI<sup>®</sup> is positioned as the first once-daily single-agent bronchodilator product for COPD patients who require, or prefer, nebulized therapy. YUPELRI<sup>®</sup>'s stability in both metered dose inhaler and dry powder device formulations suggest that this LAMA could also serve as a foundation for novel handheld combination products.

COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic antagonist.  
1. TBPH market research (N=160 physicians); refers to US COPD patients.